Concentrations of atorvastatin are increased when coadministered with Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide). Atorvastatin is metabolized by CYP3A4. Coadministration of atorvastatin (10 mg single dose) and elvitegravir/cobicistat (150/150 mg once daily, administered with emtricitabine and tenofovir alafenamide as Genvoya) was studied in 16 subjects. Elvitegravir Cmax, AUC and Cmin decreased by 9%, 8% and 12%, respectively. Atorvastatin Cmax and AUC increased by 132% and 160%. If the use of atorvastatin is considered necessary, start with the lowest dose of atorvastatin and titrate carefully while monitoring for safety. A daily dose of 40 mg atorvastatin should not be exceeded with careful safety monitoring. (Note, American treatment guidelines recommend a maximum daily dose of 20 mg for atorvastatin.) Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway.